Red Ivy Plant
Recent research at the Jawaharlal Nehru Tropical Botanic Garden & Research Institute (JNTBGRI), Kerala, has led to the development of a novel wound-healing pad. This innovation uses nanotechnology and a bioactive molecule from the red ivy plant (Strobilanthes alternata). The product promises efficient wound care with natural and synthetic components combined.
Acteoside in Red Ivy
Scientists at JNTBGRI identified acteoside, a powerful natural compound, in red ivy for the first time. Acteoside is known for its pharmacological properties but had not been linked to this plant before. This discovery underpins the wound pad’s healing effectiveness.
Design and Composition of the Wound Pad
The wound-healing pad features a multi-layered structure. It includes a thin electro-spun nanofibre layer made from biodegradable, non-toxic polymers. This layer ensures gas exchange, allowing the wound to breathe. Acteoside is incorporated at a low concentration of 0.2%, alongside the antibiotic neomycin sulfate. The polymers used are FDA-approved, ensuring safety and compatibility.
Traditional and Botanical Background of Red Ivy
Strobilanthes alternata, also called murikooti pacha locally, is a herbaceous plant native to tropical Asia. It grows up to 30 cm with purple stems and dark green leaves. Known in Ayurveda as Vranaropani, meaning wound healer, it has a long history of use in folk medicine for treating cuts and wounds.
Geographical Distribution
Red ivy thrives in tropical regions including India, Malaysia, Indonesia, China, and Japan. In Indonesia, it is traditionally used to promote urination, stop bleeding, and treat infections. It is also popular as an ornamental plant in the United States and occasionally in the United Kingdom.
Nanotechnology in Phytochemical Applications
The integration of nanotechnology with plant-based compounds marks a new era in wound care. Electro-spinning creates nanofibres that mimic natural tissue environments. This technology enhances drug delivery, improves healing rates, and reduces infection risks. The JNTBGRI team’s work exemplifies this innovative approach.
| Related | |
|---|---|
